Information Provided By:
Fly News Breaks for March 2, 2015
KERX
Mar 2, 2015 | 09:16 EDT
Roth cCapital says that the launch of Keryx;s Auryxia drug has disappointed Wall Street "at face value." However, the firm thinks that the company is doing "the blocking and tackling it needs to do regarding Medicare reimbursement" for the drug. Roth says that the drug continues to show that it has a differentiated profile. Roth cut its price target on the shares to $27 from $32 but keeps a Buy rating.
News For KERX From the Last 2 Days
There are no results for your query KERX
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.